Blueprint Medicines Corporation BPMC announced that the FDA placed a partial clinical hold on the phase I/II study of pipeline candidate BLU-222. The company is developing investigational inhibitor, ...
Real-world analysis shows BluePrint® identifies chemotherapy-sensitive Basal-type tumors among MammaPrint® High Risk HR+ HER2- breast cancers, supporting more personalized treatment strategies IRVINE, ...
A phase 2 trial has linked Blueprint Medicines’ avapritinib to statistically significant improvements in the symptoms of patients with indolent systemic mastocytosis (SM). The results tee Blueprint up ...
The FDA has placed a partial clinical hold on Blueprint Medicines Corporation's (NASDAQ: BPMC) Phase 1/2 VELA trial of BLU-222 due to visual adverse events (AEs) observed in a limited number of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback